Idiopathic autonomic neuropathy is a severe, subacute disorder with a presumed autoimmune basis. It is indistinguishable from the subacute autonomic neuropathy that may accompany lung cancer or ...

The anti–acetylcholine receptor antibody is found in 70% to 90% of patients with generalized acquired MG, according to Medscape. 2 Since 2017, the FDA has approved 3 complement inhibitors and 2 ...

Most people with generalized myasthenia gravis (gMG) have antibodies in their body that attack acetylcholine receptors at the neuromuscular junction, the place where nerve cells and muscle cells ...

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to ...

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles we use to blink, smile or even move our body around. Researchers have ...

In healthy people, binding of the molecule acetylcholine (ACh) to its receptor (AChR) on skeletal muscle cells triggers muscle contraction underlying regular daily activities. In the autoimmune ...

You’ll receive it weekly for 4 weeks, followed by every 2 weeks, and is approved for people who have tested positive for anti-acetylcholine receptor antibodies. Taking eculizumab may increase ...

The phase 3 MINT trial included more than 200 adults with anti–acetylcholine receptor antibody–positive (AChR+) or muscle-specific kinase antibody–positive (MuSK+) generalized MG.

In MG, immune proteins called antibodies mistakenly block or destroy receptors for a neurotransmitter called acetylcholine. Among other functions, acetylcholine initiates the transmission of ...

In the Phase 3 MG study, batoclimab met its primary endpoint of mean change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) score in acetylcholine receptor antibody positive ...